Semaxanib (Not yet branded)
Targeted Therapy
Description
Semaxanib (SU5416) is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR). It was developed as an anti-angiogenic agent for the treatment of metastatic colorectal cancer, designed to block tumor blood vessel formation. The drug was tested in combination with standard chemotherapy regimens including fluorouracil/leucovorin and irinotecan for advanced colorectal cancer patients.
Mechanism of Action
Semaxanib selectively inhibits VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) tyrosine kinases, which are critical for angiogenesis and tumor vascularization. By blocking VEGF signaling pathways, the drug prevents the formation of new blood vessels that tumors require for growth and metastasis. This anti-angiogenic mechanism was intended to enhance the efficacy of conventional chemotherapy in colorectal cancer treatment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Targeted Therapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.